## FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPE	ROVAL
OMB Number:	3235-0287
Estimated average	burden
hours por rosponso	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Typ	e Responses	s)													
Name and Address of Reporting Person * Noble James			2. Issuer Name and Ticker or Trading Symbol Adaptimmune Therapeutics PLC [ADAP]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable)X_ Director 10% Owner						
(Last) (First) (Middle) C/O ADAPTIMMUNE THERAPEUTICS PLC,, 60 JUBILEE AVENUE, MILTON PARK			3. Date of Earliest Transaction (Month/Day/Year) 04/01/2020						Officer (give	title below)	Othe	(specify below)			
(Street)			4. If Amendment, Date Original Filed(Month/Day/Year)					_X_1	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person						
ABINGDON, X0 OX14 4RX (City) (State) (Zip)															
		(State)		Table I - Non-Derivative Securities Acquir				•							
(Instr. 3)		2. Transaction Date (Month/Day/Year	Execut	A. Deemed Execution Date, my			(4	Securities Acqual or Disposed or nstr. 3, 4 and 5)	f(D) Own	Amount of Securities Beneficially wned Following Reported ransaction(s)			Ownership of I	Nature Indirect neficial	
				(Month/I		y/Year)			(A) or	(Inst	tr. 3 and 4)	,		Oirect (D) Over Indirect (Ir	nstr. 4)
							Co	de V A	mount (D)	Price				Instr. 4)	
Reminder: F	Report on a s	eparate line for each	01 000 01 000		1, 0	, mod dire		Person in this	s who respond orm are not re ntly valid OMB	equired to	respond ι				74 (9-02)
Reminder: F	Report on a s	eparate fine for each						Person in this t a curre	orm are not re	equired to 3 control n	respond ( umber.				74 (9-02)
1. Title of Derivative Security	2. Conversion	3. Transaction Date		- Derivat (e.g., pu 4. Transac Code	tive Suts, co	Securitie alls, war 5. Numb of Deriv Securitie Acquired or Dispo	es Accerants per rative es d (A) psed	Person in this if a curre quired, Dispos, options, co	orm are not rently valid OMB sed of, or Benefivertible securions cisable and late	equired to 3 control n ficially Owr	respond umber. ned ad Amount	8. Price of	9. Number o Derivative Securities Beneficially Owned Following	f 10. Ownership Form of Derivative Security: Direct (D)	11. Natur of Indirec Beneficia
1. Title of Derivative Security	2. Conversion or Exercise Price of Derivative	3. Transaction Date	Table II - 3A. Deemed Execution Date, if	- Derivat (e.g., pu 4. Transac Code	tive S	Securitie alls, war 5. Numb of Deriv Securitie Acquired or Dispo	es Accerants per rative es d (A) psed	Person in this is a curre quired, Dispos, options, co	orm are not rently valid OMB sed of, or Benefivertible securions cisable and late	equired to B control n ficially Own ties)  7. Title an of Underly Securities	respond umber. ned ad Amount	8. Price of Derivative Security	9. Number o Derivative Securities Beneficially Owned	f 10. Ownership Form of Derivative Security: Direct (D) or Indirect	11. Natur of Indirec Beneficia Ownershi
1. Title of Derivative Security	2. Conversion or Exercise Price of Derivative	3. Transaction Date	Table II - 3A. Deemed Execution Date, if	- Derivat (e.g., pu 4. Transac Code	tive S	Securitie alls, war 5. Numb of Deriv Securitie Acquire or Dispo of (D) (Instr. 3,	es Accerants per rative es d (A) psed	Person in this is a curre quired, Dispos, options, co	orm are not rently valid OMB sed of, or Benefivertible securions cisable and late	equired to B control n ficially Own ties)  7. Title an of Underly Securities	respond umber. ned ad Amount	8. Price of Derivative Security	9. Number o Derivative Securities Beneficially Owned Following Reported	f 10. Ownership Form of Derivative Security: Direct (D) or Indirect	11. Natur of Indirec Beneficia Ownersh
1. Title of Derivative Security	2. Conversion or Exercise Price of Derivative	3. Transaction Date	Table II - 3A. Deemed Execution Date, if	- Derivat (e.g., pu 4. Transac Code	tive S	Securitie alls, war 5. Numb of Deriv Securitie Acquire or Dispo of (D) (Instr. 3,	es Accerants per rative es d (A) psed	Person in this to a curre quired, Dispos, options, co 6. Date Exer Expiration I (Month/Day	orm are not rently valid OMB sed of, or Benefinvertible securicisable and late (Year)  Expiration	7. Title an of Underly Securities (Instr. 3 an	ned Amount ying and 4)  Amount or Number	8. Price of Derivative Security	9. Number o Derivative Securities Beneficially Owned Following Reported Transaction(	f 10. Ownership Form of Derivative Security: Direct (D) or Indirect s) (I)	11. Natur of Indired Beneficia Ownersh

### **Reporting Owners**

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Noble James C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVENUE, MILTON PARK ABINGDON, X0 OX14 4RX	X					

#### **Signatures**

/s/ James Noble	04/01/2020
Signature of Reporting Person	Date

### **Explanation of Responses:**

- $\star$  If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The exercise price was converted from GBP0.36 based on an exchange rate of \$U.S. 1.245481 to GBP1.00. The actual exercise price will be the pounds sterling amount.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.